XOMA Corporation (XOMA)
USD 19.49
(-1.62%)
USD 19.49
(-1.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -29 Million USD | 49.82% |
| 2022 | -57.79 Million USD | 37.92% |
| 2021 | -93.09 Million USD | -47.87% |
| 2020 | -62.96 Million USD | -164.1% |
| 2019 | -23.84 Million USD | -2.31% |
| 2018 | -23.3 Million USD | 19.37% |
| 2017 | -28.89 Million USD | -265.85% |
| 2016 | 17.42 Million USD | 201.9% |
| 2015 | -17.1 Million USD | 60.15% |
| 2014 | -42.9 Million USD | 29.28% |
| 2013 | -60.67 Million USD | -1310.7% |
| 2012 | -4.3 Million USD | 70.98% |
| 2011 | -14.82 Million USD | 37.23% |
| 2010 | -23.61 Million USD | -123.41% |
| 2009 | -10.56 Million USD | -119.66% |
| 2008 | 53.76 Million USD | 89.63% |
| 2007 | 28.35 Million USD | -59.62% |
| 2006 | 70.21 Million USD | 79.14% |
| 2005 | 39.19 Million USD | 267.11% |
| 2004 | -23.45 Million USD | 7.97% |
| 2003 | -25.48 Million USD | -174.83% |
| 2002 | 34.05 Million USD | 467.77% |
| 2001 | -9.26 Million USD | -285.55% |
| 2000 | 4.99 Million USD | -69.19% |
| 1999 | 16.2 Million USD | 8.72% |
| 1998 | 14.9 Million USD | 227.35% |
| 1997 | -11.7 Million USD | -186.67% |
| 1996 | 13.5 Million USD | 210.66% |
| 1995 | -12.2 Million USD | -281.25% |
| 1994 | -3.2 Million USD | 85.78% |
| 1993 | -22.5 Million USD | -1084.21% |
| 1992 | -1.9 Million USD | 48.65% |
| 1991 | -3.7 Million USD | -108.2% |
| 1990 | 45.1 Million USD | -39.22% |
| 1989 | 74.2 Million USD | 264.16% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -21.98 Million USD | -43.29% |
| 2024 Q1 | -15.33 Million USD | 47.11% |
| 2023 FY | -29 Million USD | 49.82% |
| 2023 Q1 | -44.23 Million USD | 23.47% |
| 2023 Q2 | -31.42 Million USD | 28.95% |
| 2023 Q3 | -33.47 Million USD | -6.5% |
| 2023 Q4 | -29 Million USD | 13.36% |
| 2022 Q4 | -57.79 Million USD | 26.1% |
| 2022 Q2 | -83.04 Million USD | 5.21% |
| 2022 Q1 | -87.61 Million USD | 5.89% |
| 2022 FY | -57.79 Million USD | 37.92% |
| 2022 Q3 | -78.2 Million USD | 5.84% |
| 2021 Q3 | -68.48 Million USD | 12.9% |
| 2021 FY | -93.09 Million USD | -47.87% |
| 2021 Q1 | -48.58 Million USD | 22.83% |
| 2021 Q4 | -93.09 Million USD | -35.95% |
| 2021 Q2 | -78.62 Million USD | -61.82% |
| 2020 Q2 | -17.9 Million USD | 15.73% |
| 2020 FY | -62.96 Million USD | -164.1% |
| 2020 Q3 | -15.32 Million USD | 14.43% |
| 2020 Q4 | -62.96 Million USD | -310.9% |
| 2020 Q1 | -21.24 Million USD | 10.87% |
| 2019 FY | -23.84 Million USD | -2.31% |
| 2019 Q3 | 477 Thousand USD | 105.82% |
| 2019 Q2 | -8.2 Million USD | 52.33% |
| 2019 Q4 | -23.84 Million USD | -5097.9% |
| 2019 Q1 | -17.2 Million USD | 26.16% |
| 2018 FY | -23.3 Million USD | 19.37% |
| 2018 Q1 | -27.39 Million USD | 5.2% |
| 2018 Q4 | -23.3 Million USD | -264.14% |
| 2018 Q3 | -6.39 Million USD | 73.16% |
| 2018 Q2 | -23.83 Million USD | 12.99% |
| 2017 Q4 | -28.89 Million USD | 13.54% |
| 2017 FY | -28.89 Million USD | -265.85% |
| 2017 Q1 | 6.58 Million USD | -62.22% |
| 2017 Q2 | 15.39 Million USD | 133.84% |
| 2017 Q3 | -33.42 Million USD | -317.1% |
| 2016 Q1 | 98 Thousand USD | 100.57% |
| 2016 Q2 | 12.67 Million USD | 12828.57% |
| 2016 Q4 | 17.42 Million USD | -29.17% |
| 2016 Q3 | 24.6 Million USD | 94.17% |
| 2016 FY | 17.42 Million USD | 201.9% |
| 2015 Q4 | -17.1 Million USD | -203.39% |
| 2015 FY | -17.1 Million USD | 60.15% |
| 2015 Q3 | 16.53 Million USD | 660.07% |
| 2015 Q2 | -2.95 Million USD | 85.45% |
| 2015 Q1 | -20.3 Million USD | 52.68% |
| 2014 Q1 | -34.96 Million USD | 42.38% |
| 2014 Q2 | -27.59 Million USD | 21.07% |
| 2014 Q3 | -17.47 Million USD | 36.68% |
| 2014 FY | -42.9 Million USD | 29.28% |
| 2014 Q4 | -42.9 Million USD | -145.55% |
| 2013 Q1 | -9.27 Million USD | -115.69% |
| 2013 Q4 | -60.67 Million USD | -84.07% |
| 2013 Q2 | -16.97 Million USD | -82.98% |
| 2013 Q3 | -32.96 Million USD | -94.18% |
| 2013 FY | -60.67 Million USD | -1310.7% |
| 2012 Q2 | -19.44 Million USD | 49.52% |
| 2012 Q4 | -4.3 Million USD | -95.41% |
| 2012 Q3 | -2.2 Million USD | 88.68% |
| 2012 FY | -4.3 Million USD | 70.98% |
| 2012 Q1 | -38.52 Million USD | -159.93% |
| 2011 FY | -14.82 Million USD | 37.23% |
| 2011 Q1 | -30.63 Million USD | -29.75% |
| 2011 Q2 | -24.12 Million USD | 21.24% |
| 2011 Q3 | -19.05 Million USD | 21.01% |
| 2011 Q4 | -14.82 Million USD | 22.24% |
| 2010 Q3 | -3.4 Million USD | -342.17% |
| 2010 Q4 | -23.61 Million USD | -594.41% |
| 2010 Q1 | -15.07 Million USD | -42.66% |
| 2010 FY | -23.61 Million USD | -123.41% |
| 2010 Q2 | 1.4 Million USD | 109.31% |
| 2009 Q4 | -10.56 Million USD | 27.6% |
| 2009 Q1 | 41.71 Million USD | -22.41% |
| 2009 Q2 | 27.5 Million USD | -34.06% |
| 2009 Q3 | -14.59 Million USD | -153.07% |
| 2009 FY | -10.56 Million USD | -119.66% |
| 2008 Q3 | 70.11 Million USD | 26.27% |
| 2008 Q2 | 55.52 Million USD | 63.92% |
| 2008 Q1 | 33.87 Million USD | 19.49% |
| 2008 Q4 | 53.76 Million USD | -23.32% |
| 2008 FY | 53.76 Million USD | 89.63% |
| 2007 Q2 | 32.07 Million USD | 9.95% |
| 2007 Q4 | 28.35 Million USD | 279.06% |
| 2007 FY | 28.35 Million USD | -59.62% |
| 2007 Q3 | 7.47 Million USD | -76.68% |
| 2007 Q1 | 29.17 Million USD | -58.45% |
| 2006 Q3 | 63.67 Million USD | 2.53% |
| 2006 Q2 | 62.1 Million USD | -1.65% |
| 2006 Q1 | 63.14 Million USD | 61.1% |
| 2006 Q4 | 70.21 Million USD | 10.27% |
| 2006 FY | 70.21 Million USD | 79.14% |
| 2005 FY | 39.19 Million USD | 267.11% |
| 2005 Q1 | -1.52 Million USD | 93.51% |
| 2005 Q2 | 4.33 Million USD | 384.64% |
| 2005 Q3 | 54.3 Million USD | 1152.8% |
| 2005 Q4 | 39.19 Million USD | -27.83% |
| 2004 FY | -23.45 Million USD | 7.97% |
| 2004 Q2 | -12.68 Million USD | 42.52% |
| 2004 Q3 | 12.18 Million USD | 196.01% |
| 2004 Q1 | -22.07 Million USD | 13.39% |
| 2004 Q4 | -23.45 Million USD | -292.52% |
| 2003 FY | -25.48 Million USD | -174.83% |
| 2003 Q1 | 44.62 Million USD | 31.03% |
| 2003 Q2 | 54.18 Million USD | 21.42% |
| 2003 Q3 | 3.29 Million USD | -93.93% |
| 2003 Q4 | -25.48 Million USD | -874.45% |
| 2002 Q2 | 15.64 Million USD | 1457.77% |
| 2002 Q4 | 34.05 Million USD | 13.55% |
| 2002 FY | 34.05 Million USD | 467.77% |
| 2002 Q1 | 1 Million USD | 110.84% |
| 2002 Q3 | 29.99 Million USD | 91.78% |
| 2001 Q3 | -19.14 Million USD | 30.98% |
| 2001 Q4 | -9.26 Million USD | 51.63% |
| 2001 Q2 | -27.73 Million USD | -349.52% |
| 2001 Q1 | 11.11 Million USD | 122.74% |
| 2001 FY | -9.26 Million USD | -285.55% |
| 2000 FY | 4.99 Million USD | -69.19% |
| 2000 Q1 | -10.19 Million USD | -162.93% |
| 2000 Q3 | -2.05 Million USD | 76.32% |
| 2000 Q4 | 4.99 Million USD | 342.63% |
| 2000 Q2 | -8.68 Million USD | 14.79% |
| 1999 Q3 | 27.6 Million USD | -8.0% |
| 1999 Q4 | 16.2 Million USD | -41.3% |
| 1999 Q1 | 10.8 Million USD | -27.52% |
| 1999 FY | 16.2 Million USD | 8.72% |
| 1999 Q2 | 30 Million USD | 177.78% |
| 1998 FY | 14.9 Million USD | 227.35% |
| 1998 Q2 | 600 Thousand USD | -68.42% |
| 1998 Q4 | 14.9 Million USD | 140.32% |
| 1998 Q3 | 6.2 Million USD | 933.33% |
| 1998 Q1 | 1.9 Million USD | 116.24% |
| 1997 Q3 | 4.9 Million USD | -65.25% |
| 1997 Q4 | -11.7 Million USD | -338.78% |
| 1997 FY | -11.7 Million USD | -186.67% |
| 1997 Q2 | 14.1 Million USD | 60.23% |
| 1997 Q1 | 8.8 Million USD | -34.81% |
| 1996 Q1 | -25.9 Million USD | -112.3% |
| 1996 FY | 13.5 Million USD | 210.66% |
| 1996 Q3 | 3.8 Million USD | 290.0% |
| 1996 Q4 | 13.5 Million USD | 255.26% |
| 1996 Q2 | -2 Million USD | 92.28% |
| 1995 FY | -12.2 Million USD | -281.25% |
| 1995 Q4 | -12.2 Million USD | 36.13% |
| 1995 Q2 | -1.9 Million USD | 45.71% |
| 1995 Q1 | -3.5 Million USD | -9.38% |
| 1995 Q3 | -19.1 Million USD | -905.26% |
| 1994 Q4 | -3.2 Million USD | 23.81% |
| 1994 Q1 | -6.8 Million USD | 69.78% |
| 1994 Q2 | -4.9 Million USD | 27.94% |
| 1994 Q3 | -4.2 Million USD | 14.29% |
| 1994 FY | -3.2 Million USD | 85.78% |
| 1993 Q3 | -6.1 Million USD | 28.24% |
| 1993 Q2 | -8.5 Million USD | -431.25% |
| 1993 FY | -22.5 Million USD | -1084.21% |
| 1993 Q1 | -1.6 Million USD | 15.79% |
| 1993 Q4 | -22.5 Million USD | -268.85% |
| 1992 FY | -1.9 Million USD | 48.65% |
| 1992 Q2 | -5.9 Million USD | -1083.33% |
| 1992 Q4 | -1.9 Million USD | 64.15% |
| 1992 Q1 | 600 Thousand USD | 116.22% |
| 1992 Q3 | -5.3 Million USD | 10.17% |
| 1991 FY | -3.7 Million USD | -108.2% |
| 1991 Q3 | -2.9 Million USD | 80.27% |
| 1991 Q4 | -3.7 Million USD | -27.59% |
| 1991 Q1 | 56.1 Million USD | 24.39% |
| 1991 Q2 | -14.7 Million USD | -126.2% |
| 1990 Q3 | 41.3 Million USD | -43.89% |
| 1990 Q1 | 73.6 Million USD | -0.81% |
| 1990 FY | 45.1 Million USD | -39.22% |
| 1990 Q2 | 73.6 Million USD | 0.0% |
| 1990 Q4 | 45.1 Million USD | 9.2% |
| 1989 Q2 | 78 Million USD | 0.0% |
| 1989 Q3 | 75.5 Million USD | -3.21% |
| 1989 Q4 | 74.2 Million USD | -1.72% |
| 1989 FY | 74.2 Million USD | 264.16% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 48.159% |
| Alkermes plc | -166.73 Million USD | 82.608% |
| Agenus Inc. | 274.13 Million USD | 110.579% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 101.551% |
| Aptorum Group Limited | 1.35 Million USD | 2236.995% |
| Ardelyx, Inc. | 34.51 Million USD | 184.029% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 777.57% |
| Bicycle Therapeutics plc | -481.46 Million USD | 93.977% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 180.192% |
| ChromaDex Corporation | -24.04 Million USD | -20.592% |
| Chimerix, Inc. | -25.51 Million USD | -13.65% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 516.184% |
| Caribou Biosciences, Inc. | -23.67 Million USD | -22.482% |
| CRISPR Therapeutics AG | -150.84 Million USD | 80.775% |
| Precision BioSciences, Inc. | -85.41 Million USD | 66.046% |
| Dyadic International, Inc. | -6.37 Million USD | -354.681% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -82.012% |
| Fortress Biotech, Inc. | 7.66 Million USD | 478.343% |
| Lantern Pharma Inc. | -21.7 Million USD | -33.62% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 73.764% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -239.452% |
| Incyte Corporation | -3.17 Billion USD | 99.087% |
| IO Biotech, Inc. | -140.69 Million USD | 79.389% |
| Jaguar Health, Inc. | 29.39 Million USD | 198.67% |
| Novavax, Inc. | -298.29 Million USD | 90.278% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 643.376% |
| Opthea Limited | 28.15 Million USD | 202.992% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -72.732% |
| ContextLogic Inc. | -232 Million USD | 87.5% |
| MiMedx Group, Inc. | -33.9 Million USD | 14.457% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 384.453% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -1151.604% |
| NextCure, Inc. | -6.47 Million USD | -347.738% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 42.575% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -354.617% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 338.423% |
| Vaxcyte, Inc. | -368.22 Million USD | 92.124% |
| PDS Biotechnology Corporation | -32.7 Million USD | 11.339% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 267.844% |
| Pharming Group N.V. | 109.8 Million USD | 126.411% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -66.705% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 83.45% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -56.589% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -56.589% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -308.451% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -394.881% |
| Acelyrin, Inc. | -216.9 Million USD | 86.63% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -416.909% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -1582.135% |
| Summit Therapeutics Inc. | 34.67 Million USD | 183.636% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -326.283% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1766.667% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 84.291% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 62.557% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -378.39% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 29167.145% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 4717.834% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 75.223% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 82.762% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 126.157% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -281.78% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 77.539% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 520.619% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 88.034% |
| Immix Biopharma, Inc. | -17.5 Million USD | -65.622% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 90.843% |
| MEI Pharma, Inc. | -3.7 Million USD | -682.726% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 331.796% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 117.93% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 204.343% |
| Fortress Biotech, Inc. | 7.66 Million USD | 478.343% |
| Precigen, Inc. | -481 Thousand USD | -5929.106% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 305.951% |
| AlloVir, Inc. | -62.69 Million USD | 53.742% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 47.855% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 147.028% |
| ImmuCell Corporation | 10.99 Million USD | 363.863% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 81.187% |
| Onconetix, Inc. | 5.33 Million USD | 643.943% |
| PureTech Health plc | -167.19 Million USD | 82.655% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 4.793% |
| Elevation Oncology, Inc. | -19.11 Million USD | -51.69% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -490.752% |
| Seer, Inc. | -4.24 Million USD | -583.962% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | -20.647% |
| Innoviva, Inc. | 255.56 Million USD | 111.347% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 48.088% |
| ESSA Pharma Inc. | -33.62 Million USD | 13.746% |
| GlycoMimetics, Inc. | -40.98 Million USD | 29.241% |
| GT Biopharma, Inc. | -1.02 Million USD | -2740.353% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 57.216% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 147.342% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 78.371% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -109.296% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | -0.443% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -38395.235% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 6.033% |
| Aptose Biosciences Inc. | -8.19 Million USD | -253.88% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -826.808% |
| Soligenix, Inc. | -4.95 Million USD | -485.67% |
| Century Therapeutics, Inc. | 847 Thousand USD | 3523.849% |
| Kura Oncology, Inc. | -20.11 Million USD | -44.15% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 29.14% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -245.32% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1691.924% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -807.1% |
| Autolus Therapeutics plc | -186.59 Million USD | 84.459% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 41.181% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 89.485% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 184.627% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 117.643% |
| GRI Bio, Inc. | -1.79 Million USD | -1516.499% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -222.83% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 12.8% |
| IGM Biosciences, Inc. | -72.6 Million USD | 60.058% |
| INmune Bio, Inc. | -25.41 Million USD | -14.124% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 119.212% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 42.755% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -78.468% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -905.225% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 176.286% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 29.586% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 190.952% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 107.673% |
| Verastem, Inc. | -37.27 Million USD | 22.206% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -219.63% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 44.082% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -91.609% |
| Histogen Inc. | -7.48 Million USD | -287.338% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -34.217% |
| Surrozen, Inc. | -32.66 Million USD | 11.217% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1824.353% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -589.903% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 252.952% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 1208.563% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 797.786% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -246.015% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 33.244% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -98.945% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 90.846% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -3916.287% |
| Apollomics, Inc. | -27.39 Million USD | -5.859% |
| Amarin Corporation plc | -191.04 Million USD | 84.82% |
| Mesoblast Limited | 55.96 Million USD | 151.82% |
| Turnstone Biologics Corp. | -14.58 Million USD | -98.848% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | -14.661% |
| Synaptogenix, Inc. | -28.66 Million USD | -1.181% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -2998.291% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 159.509% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3263.922% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -299.115% |
| Exelixis, Inc. | -73.05 Million USD | 60.301% |
| Better Therapeutics, Inc. | -860 Thousand USD | -3272.093% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | -20.768% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 87.985% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4039.864% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -289.883% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 2412.6% |
| Gritstone bio, Inc. | 39.49 Million USD | 173.436% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 65.518% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -1001.765% |
| Avid Bioservices, Inc. | 169.72 Million USD | 117.086% |
| Insmed Incorporated | 721.62 Million USD | 104.019% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -217.234% |
| MediWound Ltd. | -5.32 Million USD | -444.908% |
| OmniAb, Inc. | 9.2 Million USD | 415.115% |
| Alector, Inc. | -35.63 Million USD | 18.624% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 133.732% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -488.474% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 319.05% |
| Zai Lab Limited | -775 Million USD | 96.258% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 108.516% |
| Aura Biosciences, Inc. | -21.52 Million USD | -34.727% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 64.84% |
| Immunic, Inc. | -45.34 Million USD | 36.039% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 84.991% |
| Veracyte, Inc. | -203.82 Million USD | 85.772% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 104.543% |
| FibroGen, Inc. | 56.76 Million USD | 151.086% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 425.66% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -925.793% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -1300.731% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.632% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -768.004% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 82.526% |
| TG Therapeutics, Inc. | 17.86 Million USD | 262.356% |
| Galecto, Inc. | -21.21 Million USD | -36.689% |
| Calithera Biosciences, Inc. | -23.78 Million USD | -21.926% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.848% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | -18.503% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -152.021% |
| XBiotech Inc. | -200.02 Million USD | 85.502% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 65.518% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 740.459% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 17.761% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 62.444% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 609.577% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 82.983% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 68.606% |
| Vaxxinity, Inc. | 10.13 Million USD | 386.222% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 103.939% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -169.328% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 56.031% |
| NexImmune, Inc. | -3.13 Million USD | -825.44% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -739.929% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -91.907% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -7.011% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -223.082% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -23179.149% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 28.522% |
| Ainos, Inc. | 4.07 Million USD | 811.145% |
| Pluri Inc. | 22.82 Million USD | 227.031% |
| Prothena Corporation plc | -608.34 Million USD | 95.233% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 75.58% |
| Celularity Inc. | 65.19 Million USD | 144.485% |
| Rallybio Corporation | -24.1 Million USD | -20.322% |
| Cue Biopharma, Inc. | -33.81 Million USD | 14.249% |
| MeiraGTx Holdings plc | -40.3 Million USD | 28.043% |
| Omeros Corporation | 331.17 Million USD | 108.757% |
| Humacyte, Inc. | -22.48 Million USD | -28.969% |
| Immunocore Holdings plc | -358.59 Million USD | 91.913% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | -18.006% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 6.152% |
| Blueprint Medicines Corporation | 702.83 Million USD | 104.126% |
| CalciMedica, Inc. | -5.53 Million USD | -424.412% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 84.592% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -183.924% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 27.567% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 12.79% |
| Pulmatrix, Inc. | -10.41 Million USD | -178.391% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -385.193% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 23.968% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 73.968% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 51.622% |
| Cytokinetics, Incorporated | 642.37 Million USD | 104.515% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -398.025% |
| Nutriband Inc. | -251.65 Thousand USD | -11423.621% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 15.003% |
| Vor Biopharma Inc. | 4.3 Million USD | 774.419% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.52% |
| Evogene Ltd. | -19.63 Million USD | -47.703% |
| ProKidney Corp. | -56.23 Million USD | 48.432% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 40.417% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -213.948% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 102.126% |
| CorMedix Inc. | -43.05 Million USD | 32.64% |
| BioLineRx Ltd. | 7.33 Million USD | 495.311% |
| Tango Therapeutics, Inc. | -27.46 Million USD | -5.589% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 162.843% |
| Atai Life Sciences N.V. | -28.55 Million USD | -1.548% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 1400.14% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | -27.104% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 263.518% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 61.371% |
| MediciNova, Inc. | -50.78 Million USD | 42.895% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 63.2% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -128817.537% |
| GeoVax Labs, Inc. | -6.45 Million USD | -349.432% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 85.487% |
| Biomea Fusion, Inc. | -166.57 Million USD | 82.59% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 83.797% |
| Mereo BioPharma Group plc | -51.46 Million USD | 43.655% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 69.423% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 90.128% |
| Absci Corporation | -72.59 Million USD | 60.054% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 735.129% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 87.63% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 69.218% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 69.696% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 25.78% |
| Allakos Inc. | -24.97 Million USD | -16.116% |
| Imunon, Inc. | -4.21 Million USD | -588.206% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -96.717% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 78.582% |
| BioAtla, Inc. | -109.01 Million USD | 73.397% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4039.864% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -2988.392% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 342.353% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -36.773% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -75.121% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -221.65% |
| aTyr Pharma, Inc. | -7.44 Million USD | -289.314% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 76.732% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 86.069% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 64.539% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 68.738% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -3275.296% |
| Akari Therapeutics, Plc | -3.84 Million USD | -654.226% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1886.936% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.1% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2340.8% |
| UroGen Pharma Ltd. | 4.39 Million USD | 760.442% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 125.555% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 40399.047% |
| Orgenesis Inc. | 21.78 Million USD | 233.125% |
| Entera Bio Ltd. | -10.62 Million USD | -172.838% |
| GH Research PLC | -78.07 Million USD | 62.857% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | -30.115% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | -8.781% |
| Xencor, Inc. | 29.64 Million USD | 197.828% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -1372.222% |
| Replimune Group, Inc. | 1.41 Million USD | 2153.824% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -11741.181% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 77.06% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2340.8% |
| Portage Biotech Inc. | -4.98 Million USD | -482.212% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -128817.537% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 56.142% |
| OncoCyte Corporation | -6.56 Million USD | -341.871% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 3331.511% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -536.573% |
| Purple Biotech Ltd. | -14.13 Million USD | -105.121% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | -22.074% |
| scPharmaceuticals Inc. | -6.54 Million USD | -343.086% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -73.734% |
| HilleVax, Inc. | -165.48 Million USD | 82.476% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -1042.632% |
| Tharimmune, Inc. | -10.93 Million USD | -165.195% |
| Genprex, Inc. | -6.73 Million USD | -330.418% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 92.137% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 67.217% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1969.95% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -774.298% |
| OKYO Pharma Limited | -826.84 Thousand USD | -3407.295% |
| Savara Inc. | 153 Thousand USD | 19054.248% |
| Curis, Inc. | -23.88 Million USD | -21.405% |
| Daré Bioscience, Inc. | -5.15 Million USD | -462.243% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -3637.056% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -367.139% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 2547.257% |
| BeiGene, Ltd. | -2.25 Billion USD | 98.713% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 335.037% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 95.232% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 84.374% |
| Erasca, Inc. | -37.21 Million USD | 22.077% |
| bluebird bio, Inc. | 108.57 Million USD | 126.711% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2151.74% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 107.657% |
| DBV Technologies S.A. | -126.98 Million USD | 77.163% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2151.74% |
| Moderna, Inc. | -2.9 Billion USD | 99.002% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -180.139% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -166.838% |
| Molecular Templates, Inc. | 707 Thousand USD | 4201.839% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 7.558% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 108.367% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 64.661% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 68.385% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 10.139% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 15.639% |
| MacroGenics, Inc. | -66.98 Million USD | 56.707% |
| RenovoRx, Inc. | -1.17 Million USD | -2372.293% |
| Adicet Bio, Inc. | -138.78 Million USD | 79.105% |
| Prime Medicine, Inc. | -27.94 Million USD | -3.79% |
| Aditxt, Inc. | 18.12 Million USD | 260.036% |
| Adagene Inc. | -87.62 Million USD | 66.905% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -596.207% |
| Quantum-Si incorporated | -118.55 Million USD | 75.539% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 180.544% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -288.002% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 40.217% |
| SciSparc Ltd. | -2.06 Million USD | -1304.358% |
| Vericel Corporation | 1.27 Million USD | 2370.948% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -141.834% |
| Minerva Neurosciences, Inc. | 41 Million USD | 170.724% |
| Generation Bio Co. | 31.44 Million USD | 192.216% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 83.463% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 6.219% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 124.873% |
| Invivyd, Inc. | -198.47 Million USD | 85.389% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 67.874% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -1109.498% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 59.034% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -324.908% |
| 2seventy bio, Inc. | 181.71 Million USD | 115.959% |
| ADMA Biologics, Inc. | 90.06 Million USD | 132.199% |
| Clene Inc. | 3.34 Million USD | 968.263% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -219.288% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -34.815% |
| GeoVax Labs, Inc. | -6.45 Million USD | -349.432% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 91.573% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | -11.54% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 116.323% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -608.775% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 679.768% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -456.729% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 77.744% |
| Evaxion Biotech A/S | 5.28 Million USD | 648.531% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 74.238% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 77.909% |
| Trevena, Inc. | 2.25 Million USD | 1384.322% |
| Surrozen, Inc. | -32.66 Million USD | 11.217% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 43.7% |
| Cingulate Inc. | 3.08 Million USD | 1040.739% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -887.402% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 503.506% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -212.122% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 63.441% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 77.939% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 72.523% |
| Clearmind Medicine Inc. | -3.94 Million USD | -635.548% |
| Kronos Bio, Inc. | -36.05 Million USD | 19.565% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 408.216% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2088.853% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 46.55% |
| Statera Biopharma, Inc. | 14.41 Million USD | 301.16% |
| ImmunityBio, Inc. | 618.22 Million USD | 104.691% |
| Korro Bio, Inc. | -132.94 Million USD | 78.186% |
| Kineta, Inc. | -4.54 Million USD | -538.626% |
| BioVie Inc. | -17.73 Million USD | -63.543% |
| Codexis, Inc. | -43.27 Million USD | 32.981% |
| Celularity Inc. | 65.19 Million USD | 144.485% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -815.115% |
| Celcuity Inc. | 6.78 Million USD | 527.507% |
| Virax Biolabs Group Limited | -3.36 Million USD | -761.827% |
| Cibus, Inc. | -8.07 Million USD | -259.0% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -585.741% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 734.573% |
| IN8bio, Inc. | -16.38 Million USD | -76.948% |
| Kodiak Sciences Inc. | -103.87 Million USD | 72.082% |
| Annexon, Inc. | -193.75 Million USD | 85.033% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 80655.556% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -65.724% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -725.505% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.751% |
| Eyenovia, Inc. | 1.25 Million USD | 2403.961% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 207.787% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -794.234% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 12.774% |
| Arcellx, Inc. | -296.95 Million USD | 90.234% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -48.672% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 50.743% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -39.914% |
| Moolec Science SA | 117.61 Thousand USD | 24756.509% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 24.477% |
| Geron Corporation | 14.76 Million USD | 296.464% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 23.519% |
| Royalty Pharma plc | 5.65 Billion USD | 100.513% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 79.494% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -314.913% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -440.756% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 79.393% |
| Humacyte, Inc. | -22.48 Million USD | -28.969% |
| Structure Therapeutics Inc. | -124.33 Million USD | 76.677% |
| 89bio, Inc. | -289.05 Million USD | 89.967% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | -14.888% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -1526.472% |
| Genelux Corporation | -6.89 Million USD | -320.351% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 6.629% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 134.689% |
| Notable Labs, Ltd. | -9.77 Million USD | -196.645% |
| Liquidia Corporation | -80.17 Million USD | 63.83% |
| Mustang Bio, Inc. | -3.73 Million USD | -676.231% |
| Immunovant, Inc. | -635.22 Million USD | 95.435% |
| Quantum-Si incorporated | -118.55 Million USD | 75.539% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -65.11% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -599.976% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 461.281% |
| Acasti Pharma Inc. | -23 Million USD | -26.06% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -761.242% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -78.468% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 78.946% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -830.572% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -30.443% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -56.174% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 82.868% |
| PepGen Inc. | -60.67 Million USD | 52.2% |
| Moleculin Biotech, Inc. | -22.97 Million USD | -26.219% |
| United Therapeutics Corporation | -507.7 Million USD | 94.288% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -51.626% |
| Solid Biosciences Inc. | -47.75 Million USD | 39.267% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3263.922% |
| Immuneering Corporation | -54.94 Million USD | 47.218% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -589.903% |
| Silo Pharma, Inc. | -3.52 Million USD | -722.857% |
| Belite Bio, Inc | -87.27 Million USD | 66.77% |
| XOMA Corporation | -29 Million USD | -0.0% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 58.98% |
| Bionomics Limited | 227 Million USD | 112.775% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 75.061% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1044.887% |
| uniQure N.V. | -102.95 Million USD | 71.831% |
| Cassava Sciences, Inc. | -121.13 Million USD | 76.06% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -596.207% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 170.816% |
| Forte Biosciences, Inc. | -11.96 Million USD | -142.455% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -837.237% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 27458.491% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -794.234% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 425.66% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -291.046% |
| Altimmune, Inc. | -134.48 Million USD | 78.437% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 114.642% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1044.887% |
| Compugen Ltd. | -12.9 Million USD | -124.737% |
| Peak Bio, Inc. | 10.34 Million USD | 380.46% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -10147.35% |
| Benitec Biopharma Inc. | -50.58 Million USD | 42.667% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 72.206% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 247.62% |
| Zura Bio Limited | -99.8 Million USD | 70.944% |
| PolyPid Ltd. | 6.17 Million USD | 570.016% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 139.126% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 247.62% |
| Instil Bio, Inc. | 75.35 Million USD | 138.483% |
| argenx SE | -2.02 Billion USD | 98.571% |
| Immunome, Inc. | -97.02 Million USD | 70.112% |
| Compass Therapeutics, Inc. | -22.49 Million USD | -28.918% |
| Verona Pharma plc | -220.44 Million USD | 86.845% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 59.578% |
| Shattuck Labs, Inc. | -121.42 Million USD | 76.117% |
| CervoMed Inc. | -7.79 Million USD | -272.136% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 84.366% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -563.16% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 77.987% |
| Moolec Science SA | 117.61 Thousand USD | 24756.509% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -1167.495% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 282.409% |
| AnaptysBio, Inc. | -18.15 Million USD | -59.771% |
| Design Therapeutics, Inc. | -18.15 Million USD | -59.78% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 58.796% |
| NeurAxis, Inc. | 145.7 Thousand USD | 20003.912% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 358.191% |
| Lumos Pharma, Inc. | -28.49 Million USD | -1.779% |
| Achilles Therapeutics plc | -126.92 Million USD | 77.152% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 59.578% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -4322.552% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -39.599% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2088.853% |
| Nutriband Inc. | -251.65 Thousand USD | -11423.621% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -120.181% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -289.785% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 108.524% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 222.182% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 93.519% |
| Palisade Bio, Inc. | -12.06 Million USD | -140.405% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 79.332% |
| Beam Therapeutics Inc. | -262.72 Million USD | 88.962% |
| Neurogene Inc. | -131.95 Million USD | 78.023% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 232.93% |
| AEON Biopharma, Inc. | -4.88 Million USD | -494.262% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 92.312% |
| Sesen Bio, Inc. | -112.55 Million USD | 74.234% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 70.959% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -1135.203% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 25.691% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 65.179% |
| Athira Pharma, Inc. | -88.99 Million USD | 67.415% |
| Vaccinex, Inc. | -1.28 Million USD | -2151.553% |
| HCW Biologics Inc. | 2.85 Million USD | 1115.166% |
| XOMA Corporation | -29 Million USD | -0.0% |
| Nektar Therapeutics | 210.24 Million USD | 113.794% |
| Arvinas, Inc. | -313.8 Million USD | 90.758% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1886.936% |
| Merus N.V. | -192.88 Million USD | 84.965% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 148.345% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -317.988% |
| Rezolute, Inc. | -68.16 Million USD | 57.458% |
| Clene Inc. | 3.34 Million USD | 968.263% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -119.914% |
| BeyondSpring Inc. | -13.75 Million USD | -110.832% |
| Synlogic, Inc. | -6.68 Million USD | -333.807% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 2657.319% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -242.992% |
| Peak Bio, Inc. | 10.34 Million USD | 380.46% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 64.814% |
| Krystal Biotech, Inc. | -350.23 Million USD | 91.72% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 123.364% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 82.84% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -818.552% |
| MannKind Corporation | 143.89 Million USD | 120.153% |
| Ikena Oncology, Inc. | -109.15 Million USD | 73.433% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -283.041% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 12.387% |
| Gossamer Bio, Inc. | 180.35 Million USD | 116.079% |
| CohBar, Inc. | -5.93 Million USD | -388.979% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 2.514% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 735.129% |
| Legend Biotech Corporation | -949.39 Million USD | 96.945% |
| Mural Oncology plc | -255.84 Million USD | 88.665% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 190.02% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -515.627% |
| Disc Medicine, Inc. | -358.28 Million USD | 91.906% |
| Champions Oncology, Inc. | 4.81 Million USD | 702.66% |
| REGENXBIO Inc. | 54.76 Million USD | 152.951% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -10684.398% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 80.798% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -221.793% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 64.057% |
| Vaxart, Inc. | -8.24 Million USD | -251.899% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 42.208% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 77.195% |
| Cellectis S.A. | -43.85 Million USD | 33.873% |
| Longeveron Inc. | -2.9 Million USD | -897.249% |
| Repare Therapeutics Inc. | -107.85 Million USD | 73.113% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 102.995% |
| Inozyme Pharma, Inc. | 12 Million USD | 341.586% |
| Revolution Medicines, Inc. | -608.2 Million USD | 95.232% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -2257.724% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 89.061% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 80.676% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -85.339% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -3818.919% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.697% |
| Denali Therapeutics Inc. | -74.86 Million USD | 61.264% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -141.834% |
| Veru Inc. | 4.77 Million USD | 706.698% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -157.869% |
| Cingulate Inc. | 3.08 Million USD | 1040.739% |
| Passage Bio, Inc. | 4.58 Million USD | 732.497% |
| Context Therapeutics Inc. | -14.44 Million USD | -100.694% |
| Exicure, Inc. | 5.84 Million USD | 595.811% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 87.412% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 26.712% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 284.819% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 50.698% |
| Nuvalent, Inc. | -335.38 Million USD | 91.353% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1772.105% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 61.064% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -226.209% |
| OmniAb, Inc. | 9.2 Million USD | 415.115% |
| Anew Medical, Inc. | 1.43 Million USD | 2124.482% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 277.026% |
| Lipocine Inc. | -4.75 Million USD | -509.937% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 73.595% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 290.401% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 42.755% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 216.503% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -331.483% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 55.945% |
| Ocugen, Inc. | -32.52 Million USD | 10.827% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 66.112% |
| Q32 Bio Inc. | -37.94 Million USD | 23.58% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -4517.834% |
| Alumis Inc. Common Stock | -13.52 Million USD | -114.354% |
| Equillium, Inc. | -22.39 Million USD | -29.511% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | -13.423% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 11.116% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -11597.558% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 121.635% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 1006.817% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 8929.592% |
| Dominari Holdings Inc. | 195 Thousand USD | 14971.795% |
| Edesa Biotech, Inc. | -5.26 Million USD | -450.607% |
| vTv Therapeutics Inc. | -8.91 Million USD | -225.221% |
| Bio-Techne Corporation | 267.74 Million USD | 110.831% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -78.913% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 75.443% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -245.115% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -129.231% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 88.169% |
| Nkarta, Inc. | 57.29 Million USD | 150.612% |
| BioCardia, Inc. | 212 Thousand USD | 13779.245% |
| Iterum Therapeutics plc | 13.43 Million USD | 315.806% |